---
title: ADC Guide | Abzena
description: Linking Antibody to Drug with ThioBridge™ Conjugation Technology for Better ADCs in big pharma.
---

[![Abzena](https://www.abzena.bio/hubfs/Abzena%20Horizontal%20Lockup%20Gradient.svg "Abzena")](https://abzena.com/?hsLang=en)

![4X5A1130-min-1200x800](https://www.abzena.bio/hs-fs/hubfs/4X5A1130-min-1200x800.jpg?width=1200&height=800&name=4X5A1130-min-1200x800.jpg "4X5A1130-min-1200x800")

One-Pager:  Linking Antibody to Drug with ThioBridge®

## Enhance Your ADC Development with ThioBridge® Conjugation Technology

 

# Take a look at how Abzena’s ThioBridge® conjugation overcomes issues with existing technologies to give you antibody-drug conjugate (ADCs) with improved stability, potency, and efficacy.

### What’s Inside?

While ADCs are a powerful and targeted approach to therapeutics, first-generation conjugation technologies have limitations such as inconsistent drug-to-antibody ratios (DAR) and the risk of early payload detachment. Abzena’s ThioBridge® conjugation technology offers a solution by providing a more uniform DAR profile, stable linker attachment, and improved pharmacokinetic properties.

![Abzena---Thiobridge-Animated-LinkedIn-Graphics-C---1200x628---RGB---v1.1 (1)](https://www.abzena.bio/hubfs/Abzena---Thiobridge-Animated-LinkedIn-Graphics-C---1200x628---RGB---v1.1%20(1).gif "Abzena---Thiobridge-Animated-LinkedIn-Graphics-C---1200x628---RGB---v1.1 (1)")

### Send me the one pager!

Abzena Ltd © 2025. All Rights Reserved.